首頁 > 市場調查報告書 > 製藥

非專利藥

專業仿製藥市場規模、份額和趨勢分析報告：按類型（注射劑,口服）,應用（腫瘤學,炎症性疾病,丙型肝炎）,用途（專業/零售）,地區,細分市場預測2022-2030

市場調查報告書

商品編碼

1114057

專業仿製藥市場規模、份額和趨勢分析報告：按類型（注射劑,口服）,應用（腫瘤學,炎症性疾病,丙型肝炎）,用途（專業/零售）,地區,細分市場預測2022-2030

Specialty Generics Market Size, Share & Trends Analysis Report By Type (Injectables, Oral Drugs), By Application (Oncology, Inflammatory Conditions, Hepatitis C), By End-use (Specialty, Retail), By Region, And Segment Forecasts, 2022 - 2030

出版日期: 2022年07月15日 | 出版商:

Grand View Research | 英文 101 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

特種仿製藥的市場增長和趨勢

Grand View Research, Inc. 的一項新研究顯示，到 2030 年，全球特種仿製藥市場預計將達到 1487 億美元。

從 2022 年到 2030 年，市場預計將以 9.2% 的複合年增長率增長。市場增長主要受到產品批准的增加和多發性硬化症等複雜慢性病患病率上升的推動。

2022年4月，雷迪博士實驗室在美國推出甲基強的松龍琥珀酸鈉注射液，用於治療關節炎、血液疾病和某些罕見癌症患者。此外，2022 年 6 月，Elixir 啟動了旨在管理專業仿製藥定價的 Copay 解決方案增強計劃。該計劃允許符合條件的患者以零成本獲得特殊藥物的仿製藥。因此，新的低價仿製藥注射劑的推出和此類項目的可用性預計將推動市場增長。

仿製藥安全、有效且耐受性良好，由於報銷增加和更容易獲得，導致處方率更高。根據密歇根大學人力資源福利辦公室年度報告（2021 年），2020 年有 1360 例特殊仿製藥，如醋酸格拉替雷（copaxone/glatopa）、特立氟胺（Auvio）和芬戈莫德（Gilenya），2021 年約有 1,383索賠將得到解決，這意味著多發性硬化症患者的治療增加了 1.7%。

但是，與特殊仿製藥相關的高成本可能會阻礙其廣泛採用。無法吸引患者使用該藥，公司獲得了沒有仿製藥競爭對手的非專利藥物的營銷權，以及目標患者人群狹窄，這些都促成了隨後的產品價格上漲。根據密歇根大學處方藥計劃處方集報告，專業仿製藥的平均成本超過每人每月 4,500 美元，而仿製藥處方的平均成本為 17-22 美元。

特殊仿製藥市場報告亮點

按類型劃分，注射劑細分市場在 2021 年佔據市場主導地位。與口服藥物相比，由於其長效和即時吸收的高處方率，預計在預測期內將保持其主導地位。

通過應用，由於癌症患病率的增加，預計癌症區域在預測期內將出現顯著增長。據 Globocan 稱，預計未來 20 年全球新發癌症病例數將達到 2840 萬例。

就最終用戶而言，專業藥房部分在 2021 年佔據了市場主導地位，因為其具有及時交付、優化患者訪問和有效分銷管理等特點。

按地區劃分，由於存在對新產品批准的支持性監管政策，北美在 2021 年主導了市場。美國 FDA 根據 Hatch-Waxman 法案引入了仿製藥用戶費用修正案 (GDUFA)，以加快新仿製藥的批准

市場細分
- 估計/預測時間表
調查方法
信息採購
- 購買的數據庫
- GVR 內部數據庫
- 輔助信息
- 初步調查
- 初步調查的內容
信息或數據分析
- 數據分析模型
市場製定和驗證
型號詳情
- 商品流向分析
  - 方法 1：商品流通方法
  - 方法 2：使用自下而上的方法估算國別市場
全球市場：CAGR 計算
調查假設
輔助信息列表
主要信息列表
縮寫列表
目的

第 2 章執行摘要

市場概況

第 3 章市場變量、趨勢和範圍

市場系列展望
- 母公司市場展望
繪製滲透率和增長前景
監管和報銷框架
市場變量分析
- 市場驅動因素分析
  - 專利已過期的特殊藥物增加
  - 對低成本仿製藥的需求不斷增長
  - 慢性病患病率增加
  - 更加註重降低醫療保健費用
- 市場約束分析
  - 與特殊仿製藥相關的高成本
  - 新藥上市延遲
行業分析工具
- 波特五力分析
- PESTEL 分析
管道分析

第 4 章專業仿製藥市場 - 細分分析，按類型，2018-2030 年（十億美元）

專業通用市場：類型變化分析
注入
口服藥
其他

第 5 章專業仿製藥市場 - 按應用分列的細分分析，2018-2030 年（十億美元）

專業仿製藥市場：應用波動分析
腫瘤學
炎症狀況
多發性硬化症
丙型肝炎
其他

第 6 章。專業仿製藥市場 - 細分分析，按最終用途，2018-2030 年（十億美元）

專業仿製藥市場：最終用途變化分析
專業藥房
零售藥房
醫院藥房

第 7 章。專業仿製藥市場 - 2018-2030 年各地區細分分析（十億美元）

2021 年和 2030 年按地區分列的特殊仿製藥市場、市場份額
- 北美
  - 美國
  - 加拿大
- 歐洲
  - 英國
  - 德國
  - 法國
  - 西班牙
  - 意大利
- 亞太地區
  - 日本
  - 中國
  - 印度
  - 澳大利亞
  - 韓國
- 拉丁美洲
  - 巴西
  - 墨西哥
  - 阿根廷
- 中東和非洲
  - 南非
  - 沙特阿拉伯
  - 阿拉伯聯合酋長國

第 8 章專業通用市場競爭分析

分析重大交易和戰略聯盟
- 推出新產品
- 併購
- 夥伴關係和戰略合作
- 會議和活動
公司分類
- 市場差異化因素
- 創新者
- 市場領導者
供應商情況
- 主要分銷商和渠道合作夥伴列表
- 主要客戶
熱圖分析
上市公司
- 2021 年主要參與者的市場份額分析
- 公司市場分析
私人公司
- 主要初創公司列表
- 本地網絡地圖
公司簡介
- 梯瓦製藥工業有限公司
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- Viatris Inc.
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- 諾華公司（Sandoz International GmbH）
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- 費森尤斯卡比巴西有限公司
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- 馬林克羅特
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- Bausch Health Companies Inc.（Valeant Pharmaceuticals International, Inc.）
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- STADA Arzneimittel AG
  - 公司簡介
  - 財務表現
  - 產品基準
- 遠籐製藥公司
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- Apotex 公司
  - 公司簡介
  - 產品基準
  - 戰略舉措
- 太陽藥業有限公司
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- 雷迪博士實驗室有限公司
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措
- Hikma Pharmaceuticals PLC
  - 公司簡介
  - 財務表現
  - 產品基準
  - 戰略舉措

簡介目錄圖表

Product Code: GVR-1-68038-629-5

Specialty Generics Market Growth & Trends:

The global specialty generics market size is expected to reach USD 148.7 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.2% from 2022 to 2030. The growth in the market is largely driven by increasing product approvals and the rising prevalence of complex chronic diseases, such as multiple sclerosis.

In April 2022, Dr. Reddy's Laboratories launched a methylprednisolone sodium succinate injection in the U.S. for the treatment of patients with arthritis, blood disorders, and certain rare cancers. Furthermore, in June 2022, Elixir launched copay solutions enhancement program for the management of specialty generic medication prices. Under this program, an eligible patient receives a generic version of specialty medication at zero cost. Thus, the launch of new low-cost generic injectables and the availability of such programs is projected to fuel market growth.

Increased claim settlements and availability of specialty generic drugs increase their prescription rates due to the high safety, efficacy, and tolerability associated with them. According to the Human Resources Benefits Office University of Michigan annual report (2021), around 1,383 claims were settled for specialty generic drugs such as glatiramer acetate (Copaxone/Glatopa), teriflunomide (Aubagio), and fingolimod (Gilenya) in 2021, compared to 1,360 in 2020, with a rise of 1.7% for the treatment of patients with multiple sclerosis.

However, high costs associated with specialty generics may hamper their uptake. The lack of ability to attract patients toward drugs, marketing rights acquired by companies for off-patent drugs with no generic competition, and small target patient pool, subsequently increases the prices of products. According to the University of Michigan Prescription Drug Plan Formulary report, the average cost of specialty generic is over USD 4,500 monthly per person, compared to USD 17 to 22 for a generic prescription.

Specialty Generics Market Report Highlights:

Based on type, the injectables segment dominated the market in 2021. It is estimated to maintain its dominance during the forecast period due to its high prescription rate on account of long-term effects, and immediate absorption compared to oral drugs

Based on application, the oncology segment is expected to witness significant growth during the projection period owing to the increasing prevalence of cancer. According to Globocan, the number of new cancer cases is anticipated to reach 28.4 million within the next two decades worldwide

On the basis of end-use, the specialty pharmacy segment dominated the market in 2021 owing to features like timely delivery, optimized patient access, and effective distribution management

Based on region, North America dominated the market in 2021 due to the presence of supportive regulatory policies regarding the approval of new products. The U.S. FDA introduced Generic Drug User Fee Amendments (GDUFA) under the Hatch-Waxman act to quicken the approval of new generic drugs

Chapter 1 Methodology and Scope

1.1 Market Segmentation
- 1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity Flow Analysis
  - 1.6.1.1 Approach 1: Commodity Flow Approach
  - 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 List of Abbreviations
1.12 Objectives
- 1.12.1 Objective 1
- 1.12.2 Objective 2
- 1.12.3 Objective 3
- 1.12.4 Objective 4

Chapter 2 Executive Summary

2.1 Market Snapshot

Chapter 3 Market Variables, Trends, & Scope

3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Variable Analysis
- 3.4.1 Market driver analysis
  - 3.4.1.1 Rising number of off-patent specialty drugs
  - 3.4.1.2 Escalating demand for low-cost generic specialty drugs
  - 3.4.1.3 Increasing prevalence of chronic disease
  - 3.4.1.4 Increasing emphasis to cut down healthcare expenditure
- 3.4.2 Market restraint analysis
  - 3.4.2.1 High costs associated with specialty generics
  - 3.4.2.2 Delay in new drug launches
3.5 Industry Analysis Tools
- 3.5.1 Porter's five forces analysis
- 3.5.2 PESTEL Analysis
3.6 Pipeline Analysis

Chapter 4 Specialty Generics Market - Segment Analysis, by Type, 2018 - 2030 (USD Billion)

4.1 Specialty Generics Market: Type Movement Analysis
4.2 Injectables
- 4.2.1 Injectables market, 2018 - 2030 (USD Billion)
4.3 Oral Drugs
- 4.3.1 Oral drugs market, 2018 - 2030 (USD Billion)
4.4 Others
- 4.4.1 Others market, 2018 - 2030 (USD Billion)

Chapter 5 Specialty generics Market - Segment Analysis, by Application, 2018 - 2030 (USD Billion)

5.1 Specialty Generics Market: Application Movement Analysis
5.2 Oncology
- 5.2.1 Oncology market, 2018 - 2030 (USD Billion)
5.3 Inflammatory Conditions
- 5.3.1 Inflammatory conditions market, 2018 - 2030 (USD Billion)
5.4 Multiple Sclerosis
- 5.4.1 Multiple sclerosis market, 2018 - 2030 (USD Billion)
5.5 Hepatitis C
- 5.5.1 Hepatitis C market, 2018 - 2030 (USD Billion)
5.6 Others
- 5.6.1 Others market, 2018 - 2030 (USD Billion)

Chapter 6 Specialty generics Market - Segment Analysis, by End-Use, 2018 - 2030 (USD Billion)

6.1 Specialty Generics Market: End-Use Movement Analysis
6.2 Specialty Pharmacy
- 6.2.1 Specialty pharmacy market, 2018 - 2030 (USD Billion)
6.3 Retail Pharmacy
- 6.3.1 Retail pharmacy market, 2018 - 2030 (USD Billion)
6.4 Hospital Pharmacy
- 6.4.1 Hospital pharmacy market, 2018 - 2030 (USD Billion)

Chapter 7 Specialty generics Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)

7.1 Specialty Generics Market, Market Share by Region, 2021 & 2030
- 7.1.1 North America
  - 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.1.2 U.S.
  - 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.1.3 Canada
  - 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
- 7.1.2 Europe
  - 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.2.2 U.K.
  - 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.2.3 Germany
  - 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.2.4 France
  - 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.2.5 Spain
  - 7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.2.6 Italy
  - 7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
- 7.1.3 Asia Pacific
  - 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.3.2 Japan
  - 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.3.3 China
  - 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.3.4 India
  - 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.3.5 Australia
  - 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.3.6 South Korea
  - 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
- 7.1.4 Latin America
  - 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.4.2 Brazil
  - 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.4.3 Mexico
  - 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.4.4 Argentina
  - 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
- 7.1.5 Middle East and Africa
- 7.1.6 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.6.1 South Africa
  - 7.1.6.1.1 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.6.2 Saudi Arabia
  - 7.1.6.2.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
  - 7.1.6.3 UAE
  - 7.1.6.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 8 Specialty Generics Market-Competitive Analysis

8.1 Major Deals and Strategic Alliances Analysis
- 8.1.1 New Product Launch
- 8.1.2 Mergers and Acquisitions
- 8.1.3 Partnerships and Strategic Collaborations
- 8.1.4 Conferences and Campaigns
8.2 Company Categorization
- 8.2.1 Market Differentiators
- 8.2.2 Innovators
- 8.2.3 Market Leaders
8.3 Vendor Landscape
- 8.3.1 List of key distributors and channel partners
- 8.3.2 Key customers
8.4 Heat map analysis
8.5 Public Companies
- 8.5.1 Key company market share analysis, 2021
- 8.5.2 Company Market Position Analysis
8.6 Private Companies
- 8.6.1 List of key emerging companies
- 8.6.2 Regional Network Map
8.7 Company Profiles
- 8.7.1 Teva Pharmaceutical Industries Ltd
  - 8.7.1.1 Company overview
  - 8.7.1.2 Financial performance
  - 8.7.1.3 Product benchmarking
  - 8.7.1.4 Strategic initiatives
- 8.7.2 Viatris Inc.
  - 8.7.2.1 Company overview
  - 8.7.2.2 Financial performance
  - 8.7.2.3 Product benchmarking
  - 8.7.2.4 Strategic initiatives
- 8.7.3 Novartis AG (Sandoz International GmbH)
  - 8.7.3.1 Company overview
  - 8.7.3.2 Financial performance
  - 8.7.3.3 Product benchmarking
  - 8.7.3.4 Strategic initiatives
- 8.7.4 Fresenius Kabi Brasil Ltda
  - 8.7.4.1 Company overview
  - 8.7.4.2 Financial performance
  - 8.7.4.3 Product benchmarking
  - 8.7.4.4 Strategic initiatives
- 8.7.5 Mallinckrodt
  - 8.7.5.1 Company overview
  - 8.7.5.2 Financial performance
  - 8.7.5.3 Product benchmarking
  - 8.7.5.4 Strategic initiatives
- 8.7.6 Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
  - 8.7.6.1 Company overview
  - 8.7.6.2 Financial performance
  - 8.7.6.3 Product benchmarking
  - 8.7.6.4 Strategic initiatives
- 8.7.7 STADA Arzneimittel AG
  - 8.7.7.1 Company overview
  - 8.7.7.2 Financial performance
  - 8.7.7.3 Product benchmarking
- 8.7.8 Endo Pharmaceuticals Inc.
  - 8.7.8.1 Company overview
  - 8.7.8.2 Financial performance
  - 8.7.8.3 Product benchmarking
  - 8.7.8.4 Strategic initiatives
- 8.7.9 Apotex Corp.
  - 8.7.9.1 Company overview
  - 8.7.9.2 Product benchmarking
  - 8.7.9.3 Strategic initiatives
- 8.7.10 Sun Pharmaceutical Industries Ltd.
  - 8.7.10.1 Company overview
  - 8.7.10.2 Financial performance
  - 8.7.10.3 Product benchmarking
  - 8.7.10.4 Strategic initiatives
- 8.7.11 Dr. Reddy's Laboratories Ltd
  - 8.7.11.1 Company overview
  - 8.7.11.2 Financial performance
  - 8.7.11.3 Product benchmarking
  - 8.7.11.4 Strategic initiatives
- 8.7.12 Hikma Pharmaceuticals PLC
  - 8.7.12.1 Company overview
  - 8.7.12.2 Financial performance
  - 8.7.12.3 Product benchmarking
  - 8.7.12.4 Strategic initiatives

簡介目錄圖表

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 Regulatory framework
Table 4 Leading market players anticipated to witness highest growth
Table 5 List of key distributors and compounding pharmacies
Table 6 North America Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 7 North America Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 8 North America Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 9 U.S. Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 10 U.S. Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 11 U.S. Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 12 Canada Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 13 Canada Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 14 Canada Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 15 Europe Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 16 Europe Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 17 Europe Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 18 U.K. Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 19 U.K. Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 20 U.K. Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 21 Germany Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 22 Germany Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 23 Germany Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 24 France Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 25 France Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 26 France Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 27 Italy Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 28 Italy Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 29 Italy Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 30 Spain Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 31 Spain Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 32 Spain Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 33 Asia Pacific Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 34 Asia Pacific Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 35 Asia Pacific Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 36 Japan Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 37 Japan Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 38 Japan Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 39 China Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 40 China Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 41 China Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 42 India Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 43 India Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 44 India Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 45 Australia Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 46 Australia Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 47 Australia Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 48 South Korea Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 49 South Korea Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 50 South Korea Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 51 Latin America Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 52 Latin America Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 53 Latin America Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 54 Brazil Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 55 Brazil Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 56 Brazil Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 57 Mexico Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 58 Mexico Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 59 Mexico Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 60 Argentina Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 61 Argentina Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 62 Argentina Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 63 Middle East & Africa Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 64 Middle East & Africa Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 65 Middle East & Africa Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 66 South Africa Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 67 South Africa Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 68 South Africa Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 69 Saudi Arabia Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 70 Saudi Arabia Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 71 Saudi Arabia Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
Table 72 UAE Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
Table 73 UAE Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 74 UAE Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)